LanthaScreen™ Tb-pERM (pLRRKtide) Antibody Kit
LanthaScreen™ Tb-pERM (pLRRKtide) Antibody Kit
Invitrogen™

LanthaScreen™ Tb-pERM (pLRRKtide) Antibody Kit

A phospho specific antibody directed to the ezrin/radixin/moesin (ERM) peptide that is a substrate for LRRK2 (Leucine-rich repeat kinase 2)Read more
Have Questions?
Change viewbuttonViewtableView
Catalog NumberQuantity
PV49001 mg
PV489925 μg
Catalog number PV4900
Price (CNY)
387,839.00
Each
Add to cart
Quantity:
1 mg
Price (CNY)
387,839.00
Each
Add to cart

A phospho specific antibody directed to the ezrin/radixin/moesin (ERM) peptide that is a substrate for LRRK2 (Leucine-rich repeat kinase 2) and LRRK2 mutants. Mutations in LRRK2 have been found to be related to late-onset Parkinson's disease.

For use in combination with the Fluorescein-ERM (LRRKtide) substrate (Cat. No. PV4901) to evaluate inhibitors in medium to high throughput screening applications.

For Research Use Only. Not for use in diagnostic procedures.
Specifications
Antibody Molecular Weight150,000 Da
AntigenSerine/threonine kinase
Excitation/Emission340/490, 520 nm
Format384-well Plate
Gene AliasAURA17, DARDARIN, PARK8, RIPK7, ROCO
Gene ID (Entrez)120892
Packaging1 Each
Primary or SecondaryPrimary
Product LineLanthaScreen
ReactivityHuman
Reactivity abrvHu
ReadoutEnd Point
Research DisciplineProtein Assays and Analysis
Shipping ConditionDry Ice
Target EnzymeSerine/Threonine Kinases
TechniqueTR-FRET
Validated KinasesLRRK2
ApplicationsKinase Assay, Enzyme and Protein Activity Assays, Kinase Assay
ConjugateTb (Terbium)/FITC
Quantity1 mg
Regulatory StatusRUO
Unit SizeEach
Contents & Storage
Terbium-labeled anti-ERM [pLRRKtide] antibody in HEPES buffered saline. Store at -20°C.

Frequently asked questions (FAQs)

How does the LanthaScreen technology compare to other TR-FRET assay formats?

We performed a comparison between the LanthaScreen assay and other commercially available TR-FRET assays from 2 different suppliers for the PKC kinase target. Our data revealed that the assays performed comparably, but that the LanthaScreen assay was simpler to optimize and contained fewer components that required optimization. The LanthaScreen assay is a two component system, whereas the other assay formats utilize a trimolecular mechanism which is more time consuming to optimize and has added costs.

For my kinase assay, can I pre-mix the Tb-Ab and EDTA so that I can stop the kinase assay and begin detection with a single reagent addition?

Yes, this is possible depending on the concentrations of reagents used and the time for which they are mixed. We recommend developing and optimizing the assay by using separate reagent additions, because this method will work under the widest range of conditions. Once the assay is optimized, the performance of the assay using pre-mixed antibody and EDTA can be evaluated. We have successfully developed robust assays in which the antibody and EDTA were pre-mixed and then stored overnight at 4 degrees C prior to use the following day. A loss of signal intensity was observed in this case, however, by using the ratiometric readout, this effect was minimal.

Are the LanthaScreen reagents stable to interference from Mg2+, Mn2+, and EDTA?

The chelate is completely stable to Mg2+. The amount of Mn2+ or EDTA that the chelate can tolerate depends largely on how long they are mixed together and the combination of additives used in the reaction. If a reaction requires either Mg2+ or Mn2+ for activation, it is best to stop the reaction by adding an equimolar amount (or slight excess) of EDTA to chelate the metal ions present. This will then essentially eliminate any interference on the terbium chelate by EDTA or Mn2+. Regardless, when LanthaScreen assays are performed using a ratiometric readout (division of the acceptor signal by the donor signal), any interference caused by Mn2+ or EDTA is largely cancelled out.

What is the optimal and/or maximum distance for a Tb-fluorescein pair?

The Förster radius, the distance at which energy transfer efficiency is half-maximal, is around 50-angstroms for the terbiumÆ fluorescein pair. However, the Förster radius does not give a complete indication of energy transfer efficiency when using long lifetime fluorophores such as terbium chelates. When using terbium chelates, energy transfer efficiency is determined by the distance of closest approach between the donor and acceptor during the excited state lifetime of the donor. In many assay systems, such as those designed using antibodies or peptides, there is a large degree of conformational freedom that allows the donor and acceptor to approach one another, effectively enhancing the FRET signal. Additionally, it is important to note that as the donor/acceptor pair approach one another and the efficiency of energy transfer increases, the fluorescent lifetime decreases to a comparable extent. From a practical standpoint, this means that when energy transfer is extremely efficient, FRET cannot be measured in time-resolved mode (because the energy transfer is complete before the measurement is made). This is another reason why TR-FRET assays based around terbium-labeled antibodies or streptavidin perform so well, because there exist a range of donor/acceptor distances, several of which are optimal for measuring FRET.

How many LanthaScreen assays can I run with a given amount of substrate?

It varies, depending on the concentration of substrate used in the assay. But in general, for the peptide substrates, 1 mg of peptide will run approximately 250,000 wells (10 µL reaction, 200 nM peptide). For Poly GT or GAT, the 1 mL of 30 µM size we sell is approximately 1 mg. With these substrates, 1 mL of 30 µM will run approximately 16,700 wells (10 µL reaction, 200 µM substrate).

20 nmol of our physiological protein substrates is sufficient for approximately 10,000 wells (10 µL reaction, 200 µM substrate).

Citations & References (1)

Citations & References
Abstract
Investigation of leucine-rich repeat kinase 2 : enzymological properties and novel assays.
Authors:Anand VS, Reichling LJ, Lipinski K, Stochaj W, Duan W, Kelleher K, Pungaliya P, Brown EL, Reinhart PH, Somberg R, Hirst WD, Riddle SM, Steven P B,
Journal:FEBS J
PubMed ID:19076219
Mutations in leucine-rich repeat kinase 2 (LRRK2) comprise the leading cause of autosomal dominant Parkinson's disease, with age of onset and symptoms identical to those of idiopathic forms of the disorder. Several of these pathogenic mutations are thought to affect its kinase activity, so understanding the roles of LRRK2, and ... More